CD36 and chronic myelogenous leukemia, BCR-ABL1 positive: In another study, it was indicated that targeting integrin-linked kinase (ILK), which is highly upregulated in CML LSCs, can induce metabolic vulnerabilities by reduction in the CD36 expression, as a fatty acid receptor; therefore, an ILK inhibitor combined with dasatinib can increase the chance of recipient's survival [212].